Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion

키워드

참고문헌 (57)

1. Dasari A, "Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States", JAMA Oncol, 3, pp.1335~1342 (2017)
2. Yao JC, "One hundred years after"carcinoid" : epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States", J Clin Oncol, 26, pp.3063~3072 (2008)
3. Frilling A, "Recommendations for management of patients with neuroendocrine liver metastases", Lancet Oncol, 15, pp.e8~21 (2014)
4. Goksu SY, "Racial", ethnic disparities and survival characteristics in non-pancreatic gastrointestinal tract neuroendocrine tumors, 2020, pp.12, 2990~
5. 조미연, "Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study", Cancer Research and Treatment, 44(3), pp.157~165 (2012), 대한암학회[DOI]
6. Kim SJ, "Clinical course of neuroendocrine tumors with different origins(the pancreas, gastrointestinal tract, and lung)", Am J Clin Oncol, 35, pp.549~556 (2012)
7. Kim SJ, "Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors : tumor grade and metastatic site are important for treatment strategy", BMC Cancer, 10, pp.448~ (2010)
8. Pavel M, "ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms(NEN)and NEN of unknown primary site", Neuroendocrinology, 103, pp.172~185 (2016)
9. Rinke A, "Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors : a report from the PROMID Study Group", J Clin Oncol, 27, pp.4656~4663 (2009)
10. Caplin ME, "Lanreotide in metastatic enteropancreatic neuroendocrine tumors", N Engl J Med, 371, pp.224~233 (2014)
11. Yao JC, "Everolimus for advanced pancreatic neuroendocrine tumors", N Engl J Med, 364, pp.514~523 (2011)
12. Yao JC, "Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract(RADIANT-4) : a randomised, placebo-controlled, phase 3study", Lancet, 387, pp.968~977 (2016)
13. Raymond E, "Sunitinib malate for the treatment of pancreatic neuroendocrine tumors", N Engl J Med, 364, pp.501~513 (2011)
14. Strosberg J, "Phase 3 trial of(177)Lu-dotatate for midgut neuroendocrine tumors", N Engl J Med, 376, pp.125~135 (2017)
15. Kunz PL, "A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors : a trial of the ECOG-ACRIN Cancer Research Group(E2211)", J Cancer Oncol, 36, pp.4004~ (2018)
16. Kloeppel G, "WHO classification of tumours of endocrine organs", pp.209~240 (2017), IARC Press
17. WHO Classification of Tumours Editorial Board, "WHO classification of tumours: digestive system tumours" (2019), IARC Press
18. Oberg K, "Consensus on biomarkers for neuroendocrine tumour disease", Lancet Oncol, 16, pp.e435~46 (2015)
19. Deppen SA, "68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis", J Nucl Med, 57, pp.872~878 (2016)
20. Ruf J, "Impact of multiphase 68Ga-DOTATOC-PET", CT on therapy management in patients with neuroendocrine tumors, 2010, pp.91, 101~109
21. Deppen SA, "Safety and Efficacy of 68Ga-DOTATATE PET", CT for diagnosis, staging, and treatment management of neuroendocrine tumors, 2016, pp.57, 708~714
22. Frilling A, "The impact of 68Ga-DOTATOC positron emission tomography", computed tomography on the multimodal management of patients with neuroendocrine tumors, 2010, pp.252, 850~856
23. Ga-DOTA-TOC PET, "CT as a prognostic factor of lanreotide efficacy for patients with welldifferentiated gastroenteropancreatic-neuroendocrine tumours", EJNMMI Res, 10, pp.63~ (2020)
24. Kang J, "Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors : a retrospective analysis", Invest New Drugs, 37, pp.763~770 (2019)
25. Lee H, "68Ga-DOTATATE positron emission tomography-computed tomography quantification predicts response to somatostatin analog therapy in gastroenteropancreatic neuroendocrine tumors", Oncologist, 26, pp.21~29 (2021)
26. Chan J, "Targeting the mTOR signaling pathway in neuroendocrine tumors", Curr Treat Options Oncol, 15, pp.365~379 (2014)
27. Yao JC, "Efficacy of RAD001(everolimus)and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors : results of a phase II study", J Clin Oncol, 26, pp.4311~4318 (2008)
28. Yao JC, "Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy : a phase II trial", J Clin Oncol, 28, pp.69~76 (2010)
29. Oh DY, "Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas", paragangliomas, 2012, pp.118, 6162~6170
30. Yoo C, "Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor", Cancer Chemother Pharmacol, 79, pp.139~146 (2017)
31. Pavel ME, "Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome(RADIANT-2) : a randomised, placebo-controlled, phase 3 study", Lancet, 378, pp.2005~2012 (2011)
32. Motzer RJ, "Efficacy of everolimus in advanced renal cell carcinoma : a double-blind, randomised, placebo-controlled phase III trial", Lancet, 372, pp.449~456 (2008)
33. Baselga J, "Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer", N Engl J Med, 366, pp.520~529 (2012)
34. Pavel ME, "Health-related quality of life for everolimus versus placebo in patients with advanced, nonfunctional, well-differentiated gastrointestinal or lung neuroendocrine tumours(RADIANT-4) : a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial", Lancet Oncol, 18, pp.1411~1422 (2017)
35. Strosberg JR, "A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors", Ann Oncol, 23, pp.2335~2341 (2012)
36. Kulke MH, "Activity of sunitinib in patients with advanced neuroendocrine tumors", J Clin Oncol, 26, pp.3403~3410 (2008)
37. Phan AT, "Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours : a multicentre, single-group, phase 2 study", Lancet Oncol, 16, pp.695~703 (2015)
38. 38 Grande E, "Pazopanib in pretreated advanced neuroendocrine tumors : a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors(GETNE)", Ann Oncol, 26, pp.1987~1993 (2015)
39. Ahn HK, "Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours", Br J Cancer, 109, pp.1414~1419 (2013)
40. Chan JA, "Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors", J Clin Oncol, 30, pp.2963~2968 (2012)
41. Castellano D, "Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour : a phase II study of Spanish Neuroendocrine Tumour Group(GETNE0801)", Eur J Cancer, 49, pp.3780~3787 (2013)
42. Yao JC, "Targeting vascular endothelial growth factor in advanced carcinoid tumor : a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b", J Clin Oncol, 26, pp.1316~1323 (2008)
43. Brabander T, "Peptide receptor radionuclide therapy of neuroendocrine tumours", Best Pract Res Clin Endocrinol Metab, 30, pp.103~114 (2016)
44. octreotate : toxicity, efficacy, and survival, "J Clin Oncol", 2008, 2124~2130
45. octreotate in patients with endocrine gastroenteropancreatic tumors, "J Clin Oncol", 2005, 2754~2762
46. Sabet A, "Advances in peptide receptor radionuclide therapy", Semin Nucl Med, 46, pp.40~46 (2016)
47. Kouvaraki MA, "Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas", J Clin Oncol, 22, pp.4762~4771 (2004)
48. Moertel CG, "Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma", N Engl J Med, 326, pp.519~523 (1992)
49. Dilz LM, "Streptozocin", 5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours, 2015, pp.51, 1253~1262
50. Clewemar Antonodimitrakis P, "Streptozocin and 5-fluorouracil for the treatment of pancreatic neuroendocrine tumors : efficacy, prognostic factors and toxicity", Neuroendocrinology, 103, pp.345~353 (2016)
51. Strosberg JR, "First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas", Cancer, 117, pp.268~275 (2011)
52. Fine RL, "Capecitabine and temozolomide(CAPTEM)for metastatic, well-differentiated neuroendocrine cancers : the Pancreas Center at Columbia University experience", Cancer Chemother Pharmacol, 71, pp.663~670 (2013)
53. Sorbye H, "Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma(WHO G3) : the NORDIC NEC study", Ann Oncol, 24, pp.152~160 (2013)
54. Kulke MH, "A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors", Dig Dis Sci, 51, pp.1033~1038 (2006)
55. Noda K, "Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer", N Engl J Med, 346, pp.85~91 (2002)
56. Patel SP, "A phase II basket trial of dual anti-CTLA-4 and antiPD-1 blockade in rare tumors(DART SWOG 1609)in patients with nonpancreatic neuroendocrine tumors", Clin Cancer Res, 26, pp.2290~2296 (2020)
57. Pavel M, "Gastroenteropancreatic neuroendocrine neoplasms : ESMO clinical practice guidelines for diagnosis, treatment and follow-up", Ann Oncol, 31, pp.844~860 (2020)

관련 논문AI추천